Silo Pharma (SILO) Stock Announces Alzheimer’s Disease News

Silo Pharma SILO Stock News

Silo Pharma, Inc. (OTCQB: SILO), a company focused on the use of psychedelics, like psilocybin, as therapeutics, made a huge announcement this morning. According to a press release from the company, it has entered an agreement with Columbia University surrounding the treatment of Alzheimer’s disease. Here’s what’s going on:

Silo Announces Research Agreement

In the press release, Silo Pharma said that it has entered into a sponsored research agreement with Columbia University. Under the agreement, the company has been granted the option to license certain assets currently under development with indications including, but not limited to, Alzheimer’s disease. 

In the release, the company said that the agreement incorporates the work of Dr. Christine Ann Denny, an Associate Professor of Clinical Neurology at Columbia University Irving Medical Center. 

Denny and her team have focused their efforts on the molecular mechanisms underlying learning and memory, including diseases like Alzheimer’s disease. 

This is a massive indication. After all, it is estimated that 5.8 million Americans, including one in 10 people over age 65 or older currently live with Alzheimer’s disease. 

Dr. Denny and her team are pioneering treatment options, researching whether ketamine and the novel inventions that may be licensed by Silo may improve memory retrieval, halt, or even reverse, the process of Alzheimer’s disease-related to memory loss or cognitive aging. If all works out, these therapeutic options will have life-altering implications for people suffering with everything from Alzheimer’s disease to PTSD. 

Management Commentary

In a statement, Eric Weisblum, CEO at SILO, had the following to offer:

We are excited to partner with Dr. Denny and Columbia University, a world-renowned institution that is at the forefront of research and development in this area. To be able to bring hope and possibly a therapeutic to patients suffering from Alzheimer’s disease is an exciting proposition for Silo Pharma. The unique compounds being developed at Columbia have shown tremendous promise, and we look forward to continuing to explore and develop this therapeutics.

Final Thoughts

All told, the news released by Silo proved to be overwhelmingly positive. After all, the new assets that the company has the potential to license could provide the solution to many patients suffering with Alzheimer’s disease and other neurological conditions. All in all, SILO stock is one to watch closely. 

Disclosure. CNA Finance is not a financial advisor or broker dealer. Trading in penny stocks can lead to a significant loss of capital. Joshua Rodriguez, the author of this article, is the founder of CNA Finance, LLC. CNA Finance has a financial relationship with Silo Pharma.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.